TOP TEN perturbations for NM_000332 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000332
Selected probe(set): 203232_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000332 (203232_s_at) across 5339 perturbations tested by GENEVESTIGATOR:

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):-4.8424673
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

zalypsis study 1 / untreated MM1S cell sample

Relative Expression (log2-ratio):-4.598027
Number of Samples:2 / 2
Experimental zalypsis study 1
MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated MM1S cell sample
MM1S multiple myeloma cells untreated.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):4.497279
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):4.321042
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-4.127426
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

plicamycin study 2 (100 nM) / vehicle (PBS) treated TC-71 cell sample

Relative Expression (log2-ratio):-3.479744
Number of Samples:3 / 3
Experimental plicamycin study 2 (100 nM)
TC-71 Ewing?s sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code:
Control vehicle (PBS) treated TC-71 cell sample
TC-71 Ewing?s sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours.

immune cell study 6 (PB; memory) / immune cell study 6 (PB; CD21hi)

Relative Expression (log2-ratio):3.3568954
Number of Samples:2 / 2
Experimental immune cell study 6 (PB; memory)
Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control immune cell study 6 (PB; CD21hi)
Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21hi) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21hi.

immune cell study 6 (PB; memory) / immune cell study 6 (PB; CD21lo)

Relative Expression (log2-ratio):3.1408615
Number of Samples:2 / 2
Experimental immune cell study 6 (PB; memory)
Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control immune cell study 6 (PB; CD21lo)
Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):3.0213327
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

plicamycin study 1 (100 nM) / vehicle (PBS) treated TC-32 cell sample

Relative Expression (log2-ratio):-3.0015454
Number of Samples:3 / 3
Experimental plicamycin study 1 (100 nM)
TC-32 Ewing?s sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code:
Control vehicle (PBS) treated TC-32 cell sample
TC-32 Ewing?s sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours.